Program
benralizumab
Also written as “Benralizumab”, “Benralizumab 100 mg” and “KHK4563”.
Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Churg-Strauss Syndrome · Nasal Polyps · Hypereosinophilic Syndrome, led by 2 companies.
Drug pageBenralizumab: every studyAll 67 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 465 open or running | phase 4since Apr 10, 2019 | Aug 6, 2007 | Dec 23, 2026phase 3 · NCT05692180 |
| Kyowa Kirin | 20 open or running | phase 2since Aug 7, 2011 | Aug 7, 2011 | none ahead |
Also a collaborator on its studies: Parexel, Iqvia Pty, Covance and PPD DEVELOPMENT, LP.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Kyowa Kirin only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 7, 2011First study: phase 2 study in Uncontrolled and Suspected Eosinophilic AsthmaFirst studyNCT01412736 · 106 enrolled · Japan, Korea, Republic of
- Apr 25, 2016Phase 2 study in Eosinophilic Chronic RhinosinusitisNCT02772419 · 63 enrolled · Japan
TargetBeta
“Interleukin-5 receptor subunit alpha inhibitor”ChEMBL 37, by rule
Studies
All 2 Kyowa Kirin leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02772419Eosinophilic Chronic Rhinosinusitis · Japan | 2 | Completed | Mar 27, 2017 | 63 |
| NCT01412736Uncontrolled and Suspected Eosinophilic Asthma · Japan, Korea, Republic of | 2 | Completed | Jul 2013 | 106 |
How it is read
Names in the registry
- “Benralizumab”, 38 entries
- “benralizumab”, 3 entries
- “Benralizumab 100 mg”, 3 entries
- “KHK4563”, 3 entries
- “MEDI-563”, 3 entries
Conditions, from the studies’ own filings
- Asthma, 29 studies
- Pulmonary Disease, Chronic Obstructive, 4 studies
- Churg-Strauss Syndrome, 2 studies
- Nasal Polyps, 2 studies
- Hypereosinophilic Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.